Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.49 |
| ▸ | ITGB1 | P05556 | 11/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 11/20 | 0.43 |
| ▸ | ITGB7 | P26010 | 5/20 | 0.43 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.43 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.43 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.43 |
| ▸ | ITGAL | P20701 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3237956 | 0.92 | L3MBTL1 (0.46) | UTS2RITGB2ICAM1ITGALCCR5 | |
| SCHEMBL3906111 | 0.86 | UTS2R (0.50) | UTS2RITGB1ITGA4ITGB7ITGA2 | |
| SCHEMBL3237990 | 0.83 | L3MBTL1 (0.47) | UTS2RITGB2ICAM1ITGALCCR5 | |
| SCHEMBL3238600 | 0.82 | UTS2R (0.46) | UTS2RL3MBTL1LMNA | |
| SCHEMBL3238502 | 0.79 | L3MBTL1 (0.47) | UTS2RITGB2ICAM1ITGALL3MBTL1 | |
| SCHEMBL3902170 | 0.78 | LMNA (0.44) | UTS2RITGB1ITGA4L3MBTL1SLC6A9 | |
| SCHEMBL3241715 | 0.78 | SLC6A9 (0.42) | UTS2RITGB1ITGA4ITGB7ITGA2 | |
| SCHEMBL3907148 | 0.77 | SLC6A9 (0.47) | UTS2RITGB2ICAM1ITGALL3MBTL1 | |
| SCHEMBL3239589 | 0.75 | L3MBTL1 (0.40) | UTS2RITGB2ICAM1ITGALCCR5 | |
| SCHEMBL3244398 | 0.75 | CTSS (0.55) | SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-20080287547-A1 | Glycine Transport Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080287547-A1 | Glycine Transport Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080287547-A1 | Glycine Transport Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287547-A1 | Glycine Transport Inhibitors | SLC18A2, SLC6A5, SLC1A2 | UTS2R 3013/4885ITGB1 4772/4885ITGA4 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.